STAAR Surgical Company (STAA)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.32B
Last updated: Nov 17, 2026 at 11:05 AM ET
STAAR Surgical Company (STAA) Stock Forecast
Analysts expect STAAR Surgical Company (STAA) to earn $0.93 per share in the fiscal year ending Dec 31, 2026, on revenue of $338.94M. Of 11 analysts, 4 rate the stock Buy or Strong Buy, 6 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.73, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 36% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 36.4% |
| Hold | 6 | 54.5% |
| Sell | 1 | 9.1% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 21.5% and revenue estimates rise 8.2%.
- Fiscal year ending Dec 31, 2026
- $0.93
- EPS consensus, revenue $338.94M
- Fiscal year ending Dec 31, 2027
- $1.13
- EPS consensus, revenue $366.60M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.93 | $0.82 to $1.07 | 4 | $338.94M | $333.99M to $346.90M | 9 |
| Dec 31, 2027 | $1.13 | $1.06 to $1.19 | 4 | $366.60M | $332.00M to $384.70M | 11 |
Quarterly Estimates
The EPS consensus rises from -$0.06 for the quarter ending Dec 31, 2026 to $0.35 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.06 | -$0.13 to $0.00 | 12 | $69.72M | $62.25M to $79.10M | 12 |
| Mar 31, 2027 | $0.35 | $0.29 to $0.41 | 3 | $101.58M | $94.20M to $105.10M | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 4 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 25.7% from $0.74.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.93 | $0.84 | $0.84 | $0.76 | $0.74 | +26.1% |
| Fiscal year ending Dec 31, 2027 | $1.13 | $1.11 | $1.11 | $1.02 | $0.99 | +14.5% |
| Quarter ending Mar 31, 2027 | $0.35 | $0.37 | $0.37 | $0.32 | $0.29 | +18.7% |
Frequently Asked Questions About STAA
What is the STAA stock forecast?
Consensus analyst estimates put STAAR Surgical Company's EPS at $0.93 for the fiscal year ending Dec 31, 2026, on revenue of $338.94M. The consensus rating from 11 analysts is Hold.
How do analysts rate STAA stock?
Of 11 analysts covering STAAR Surgical Company, 0 rate it Strong Buy, 4 Buy, 6 Hold, 1 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from STAA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.93, with estimates from $0.82 to $1.07 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.13, with estimates from $1.06 to $1.19 from 4 analysts.
What revenue do analysts expect from STAAR Surgical Company next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $338.94M, with estimates from $333.99M to $346.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $366.60M, with estimates from $332.00M to $384.70M.
How many analysts cover STAA?
11 analysts rate STAAR Surgical Company stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
STAA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts